natgillin/translations-raw huggingface dataset:
Solution for injection
FARMACEVTSKA OBLIKA raztopina za injiciranje
300 mg q4wks
300 mg vsake 4 tedne
Subcutaneous use Read the package leaflet before use For single use only
POSTOPEK UPORABE Pred uporabo preberite priloženo navodilo!
TAKHZYRO 300 mg solution for injection lanadelumab This medicine is subject to additional monitoring.
IME ZDRAVILA IN POT(I) UPORABE TAKHZYRO 300 mg raztopina za injiciranje lanadelumab subkutana uporaba
Secondary endpoint - Number of HAE attacks requiring acute treatment from Day 0 to 182 LS Mean (95% CI) monthly attack rate b
Sekundarni opazovani dogodek - število napadov HAE, ki jih je bilo treba akutno zdraviti, od 0. do 182. dneva
pointed-tip injection needle to the syringe.
f) Injekcijsko iglo s konico za dajanje velikosti
• One 18 gauge blunt tip vial access needle.
• Eno iglo za dostop do viale premera 18G s topo konico.
GENERAL CLASSIFICATION FOR SUPPLY
Rezultat za prehranjevanje
TAKHZYRO total
Zdravilo TAKHZYRO skupaj
What you need to know before you use TAKHZYRO 3.
Kaj je zdravilo TAKHZYRO in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo TAKHZYRO Kako uporabljati zdravilo TAKHZYRO Možni neželeni učinki
Criteria
DRUGI PODATKI
Return the syringe to an upright position.
Pritrdite iglo s topo konico za dostop do viale.
• Muscle pain
NALEPKA (VIALA)
UNIT PACK CARTON
ŠTEVILKA SERIJE Lot
Adverse drug reaction
Neželeni učinek zdravila
Each vial contains 300 mg lanadelumab.
NAVEDBA ENE ALI VEČ UČINKOVIN Ena viala vsebuje 300 mg lanadelumaba.
20 October 2011
20. oktober 2011
The final opinion was converted into a Decision by the European Commission on 20 October 2011.
Končno mnenje je bilo spremenjeno v sklep Evropske komisije dne 20. oktobra 2011.
The referral procedure started on 14 April 2010.
Napotitveni postopek se je začel dne 14. aprila 2010.
Veterinary Medicines and Product Data Management
Veterinarska zdravila in upravljanje podatkov o zdravilu
The Committee appointed Dr Bruno Urbain as rapporteur and Mrs Ruth Kearsley as co-rapporteur.
Odbor je za poročevalca določil dr. Bruna Urbaina, za soporočevalko pa go. Ruth Kearsley.
The list of product names concerned is given in Annex I. The scientific conclusions are provided in Annex II, together with the amended summary of product characteristics in Annex III.
Seznam zadevnih imen zdravil je naveden v Prilogi I. Znanstveni zaključki so na voljo v Prilogi II, dopolnjeni povzetek glavnih značilnosti zdravila pa v Prilogi III.
Due to the divergent national decisions taken by Member States concerning the authorisation of Synulox Lactating Cow and associated names and differences between the summary of product characteristics (SPC) of the product as authorised in the Member States, the issue was referred on 26 March 2010 by Belgium and Denmark to the CVMP under Article 34(1) of Directive 2001/82/EC.
Zaradi različnih nacionalnih odločitev držav članic v zvezi z odobritvijo zdravila Synulox Lactating Cow in povezana imena ter razlik med povzetki glavnih značilnosti zdravila (SPC), odobrenimi v državah članicah, sta Belgija in Danska zadevo dne 26. marca 2010 napotili na CVMP v skladu s členom 34(1) Direktive 2001/82/ES.
Written explanations were provided by the marketing authorisation holders on 18 August 2010 and 8 February 2011.
Imetniki dovoljenja za promet z zdravilom so pisne razlage podali dne 18. avgusta 2010 in 8. februarja 2011, ustne obrazložitve pa 4. maja 2011.
The reason for divergent national decisions regarding the authorisation of the products was mainly the justification of the combination of amoxicillin/clavulanic acid/prednisolone for the treatment of bovine mastitis.
Razlog za razlike med nacionalnimi odločitvami o odobritvi zdravil je bil v glavnem v utemeljitvi kombinacije amoksicilin/klavulanska kislina/prednizolon za zdravljenje bovinega mastitisa.
The product is intended for the treatment of bovine clinical mastitis in lactating cows.
Zdravilo je namenjeno zdravljenju bovinega kliničnega mastitisa pri kravah v obdobju laktacije.
Further to the resignation of Mrs Ruth Kearsley as CVMP member, Ms Helen Jukes was appointed to replace her and took over the co-rapporteurship.
Ruth Kearsley z mesta članice CVMP je bila kot zamenjava določena ga. Helen Jukes, ki je prevzela vlogo soporočevalke.
International non-proprietary name (inn): amoxicillin trihydrate, potassium clavulanate, prednisolone
Mednarodno nelastniško ime (INN): amoksicilin trihidrat, kalijev klavulanat, prednizolon
Synulox Lactating Cow and associated names is a 3 g pale cream/buff coloured oily suspension presented in disposable intramammary syringes containing 200 mg amoxicillin as amoxicillin trihydrate, 50 mg clavulanic acid as potassium clavulanate and 10 mg prednisolone.
Zdravilo Synulox Lactating Cow in povezana imena je na voljo v intramamarnih brizgah za enkratno uporabo, ki vsebujejo 3 g oljne suspenzije svetlo kremne/bež barve z 200 mg amoksicilina v obliki amoksicilin trihidrata, 50 mg klavulanske kisline v obliki kalijevega klavulanata in 10 mg prednizolona.
This combination is effective against β-lactamase producing organisms.
Ta kombinacija je učinkovita proti organizmom, ki tvorijo β-laktamaze.
Amoxicillin is a broad spectrum bactericidal β-lactam antibiotic.
Amoksicilin je baktericidni β-laktamski antibiotik širokega spektra.
Prednisolone is an anti-inflammatory corticosteroid.
Prednizolon je protivnetni kortikosteroid.
The main sections of disharmony of the existing SPCs related to indications, posology and withdrawal periods.
Nesoglasja v obstoječih povzetkih glavnih značilnosti zdravila zadevajo poglavja, ki se nanašajo na indikacije, odmerjanje in obdobja karence.
Based on the rapporteurs' assessment of the currently available data, the CVMP considered that the benefit/risk profile for Synulox Lactating Cow and associated names remains positive subject to
CVMP je na podlagi ocene trenutno razpoložljivih podatkov, ki sta jo pripravila poročevalca, menil, da po spremembi dovoljenj za promet z zdravilom v skladu s povzetkom glavnih značilnosti zdravila razmerje med koristmi in tveganji za zdravilo Synulox Lactating Cow in povezana imena ostaja pozitivno, zato je dne 7. junija 2011 sprejel pozitivno mnenje.
Clavulanic acid inactivates β-lactamases.
Klavulanska kislina inaktivira betalaktamaze.
This summary was last updated in January 2012.
Povzetek je bil nazadnje posodobljen januarja 2012.
In very rare cases, they may be serious or fatal.
V zelo redkih primerih so lahko resni ali povzročijo smrtni izid.
These side effects occur usually within the first week of treatment and are generally temporary.
Običajno se pojavijo v prvem tednu zdravljenja in so ponavadi začasni.
The European Commission granted a marketing authorisation valid throughout the European Union, for Acticam on 9 December 2008.
Evropska komisija je dovoljenje za promet z zdravilom Acticam, veljavno po vsej Evropski uniji, odobrila dne 9. decembra 2008.
Other information about Acticam:
Druge informacije o zdravilu Acticam:
What benefit has Acticam shown during the studies?
Kakšne koristi je zdravilo Acticam izkazalo med študijami?
They disappear once treatment has stopped.
Po prekinitvi zdravljenja izzvenijo.
Acticam has been investigated in comparison with Metacam which is already authorised in the EU.
Zdravilo Actican so proučevali v primerjavi z zdravilom Metacam, ki že ima dovoljenje za promet v EU.
If the product is swallowed by a person, the advice of a doctor should be sought immediately.
V primeru, da zdravilo nenamerno zaužije človek, se je treba nemudoma posvetovati z zdravnikom.
What is the risk associated with Acticam?
Kakšna tveganja so povezana z zdravilom Acticam?
Why has Acticam been approved?
Zakaj je bilo zdravilo Acticam odobreno?
People with known hypersensitivity (allergic) to meloxicam should avoid contact with the product.
Osebe z znano preobčutljivostjo (alergijo) za nesteroidna protivnetna zdravila naj se izogibajo stiku z zdravilom.
Meloxicam acts by inhibition of prostaglandin synthesis.
Meloksikam učinkuje tako, da zavira sintezo prostaglandinov.
Acticam should not be administered to pregnant or lactating animals as the safety of the product has not been established in these cases.
Zdravilo Acticam se ne sme uporabljati pri brejih živalih ali živalih v obdobju laktacije, ker varnost zdravila v teh primerih ni bila ugotovljena.
Studies have been carried out to prove that Acticam is ‘bioequivalent' to the reference veterinary medicine: this means that Acticam is equivalent to Metacam 1.5 mg/ml suspension in the way it is absorbed and used by the body.
Študije so pokazale, da je zdravilo Acticam „biološko enakovredno“ referenčnemu veterinarskemu zdravilu, to pomeni, da je zdravilo Acticam enako zdravilu Metacam 1,5 mg/ml peroralna suspenzija glede načina, kako ga telo absorbira in uporabi.
Acticam contains meloxicam, which belongs to a class of medicines called non-steroidal antiinflammatory drugs (NSAIDs).
Zdravilo Acticam vsebuje meloksikam, ki spada v skupino zdravil, ki jim pravimo nesteroidna protivnetna zdravila (NSPVZ).
Acticam should also not be used in animals suffering from gastrointestinal or hemorrhagic disorders and impaired renal or hepatic function, animals with known hypersensitivity to NSAIDs, and animals less than 6 weeks of age or in cats of less than 2 kg.
Zdravilo Acticam se ne sme uporabljati pri živalih z obolenji prebavil ali hemoragičnih obolenjih ter pri motnjah jetrne ali ledvične funkcije, živalih z ugotovljeno preobčutljivostjo na nesteroidna protivnetna zdravila ter živalih, mlajših od 6 tednov, ali mačkah, lažjih od 2 kg.
A study looked at how Acticam was absorbed and its effects in the body, in comparison with Metacam oral suspension 1.5mg/ml.
V študiji so proučevali absorbiranje zdravila Acticam ter njegove učinke na telo v primerjavi z zdravilom Metacam 1,5 mg/ml peroralna suspenzija.
What is Acticam used for?
Za kaj se zdravilo Acticam uporablja?
As the prostaglandins are substances that trigger inflammation, pain, exudation and fever, meloxicam reduces those responses.
Prostaglandini so snovi, ki povzročajo vnetje, bolečino, izločanje tekočine in zvišano telesno temperaturo, meloksikam pa zmanjšuje obseg teh odzivov.
The Committee for Medicinal Products for Veterinary Use (CVMP) considered that, in accordance with European Union requirements, Acticam has been shown to be bioequivalent to Metacam
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je menil, da se je zdravilo Acticam v skladu z zahtevami Evropske unije izkazalo kot biološko enakovredno zdravilu Metacam 1,5 mg/ml peroralna suspenzija.
Occasional side effects of Acticam are those seen with NSAIDs, such as loss of appetite, vomiting, diarrhoea, blood appearing in the stools and apathy (lack of vitality).
Občasni neželeni učinki zdravila Acticam so enaki kot pri drugih nesteroidnih protivnetnih zdravilih in vključujejo izgubo teka, bruhanje, drisko, kri v blatu in apatijo (pomanjkanje vitalnosti).
Acticam is presented as an oral suspension 1.5 mg/ml for dogs (to be given mixed with food) and a solution for injection 5mg/ml.
Zdravilo Acticam je na voljo v obliki peroralne suspenzije za pse v odmerku 1,5 mg/ml (ki se zmeša s hrano) in raztopine za injiciranje v odmerku 5 mg/ml.
In case of accidental self-injection, medical advice should be sought immediately showing the package leaflet or the label to the physician.
V primeru nenamernega samoinjiciranja se takoj posvetujte z zdravnikom in mu pokažite navodilo za uporabo ali ovojnino.
An oral follow-up therapy using meloxicam or other NSAIDs should not be used in cats, as no safe dosage for repeated oral administration has been established.
Pri mačkah zdravljenja ne smete nadaljevati s peroralno obliko meloksikama ali drugega nesteroidnega protivnetnega zdravila, ker pri njih še ni določen varen odmerek za takšno nadaljevalno peroralno zdravljenje.
Acticam contains meloxicam which belongs to a class of medicines having anti-inflammatory action.
Zdravilo Acticam vsebuje meloksikam, ki spada v skupino zdravil s protivnetnim delovanjem.
How does Acticam work?
Kako zdravilo Acticam deluje?
How has Acticam been studied?
Kako je bilo zdravilo Acticam raziskano?
The CVMP concluded that the benefits of Acticam exceed the risks for the alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders, reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery in dogs and reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery in cats and recommended that Acticam be given a marketing authorisation.
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je zaključil, da so koristi zdravila Acticam pri umirjanju vnetja in lajšanju bolečine pri akutnih in kroničnih mišičnoskeletnih obolenjih, lajšanju pooperativne bolečine in vnetja po ortopedskih operacijah in operacijah mehkega tkiva pri psih ter lajšanju pooperativne bolečine po ovariohisterektomiji in manjših operacijah mehkega tkiva pri mačkah večje od z njim povezanih tveganj, in priporočil, da se za zdravilo Acticam odobri dovoljenje za promet.
Acticam is a ‘generic': this means that Acticam is similar to a ‘reference veterinary medicine' already authorised in the EU (Metacam 1.5 mg/ml oral suspension).
To pomeni, da je podobno „referenčnemu veterinarskemu zdravilu“, ki je že bilo odobreno v EU (zdravilu Metacam 1,5 mg/ml peroralna suspenzija).
What is Acticam?
Kaj je zdravilo Acticam?
Dogs: Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders and reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery.
Psi: Umirjanje vnetja in lajšanje bolečine pri akutnih in kroničnih mišično-skeletnih obolenjih ter lajšanje pooperativne bolečine in zmanjšanje vnetja po ortopedskih operacijah in operacijah mehkega tkiva.
Acticam is efficacious in alleviating the inflammation and pain in both acute and chronic musculoskeletal disorders and reducing the post operative pain following orthopaedic and soft tissue surgery in dogs and in reducing the post-operative pain after ovariohysterectomy and minor soft tissue surgery in cats.
Zdravilo Acticam je učinkovito pri umirjanju vnetja in lajšanju bolečine pri akutnih in kroničnih mišično-skeletnih obolenjih ter lajšanju pooperativne bolečine po ortopedskih operacijah in operacijah mehkega tkiva pri psih ter lajšanju pooperativne bolečine po ovariohisterektomiji in manjših operacijah mehkega tkiva pri mačkah.
This summary was last updated in 11-2015.
Povzetek je bil nazadnje posodobljen 11-2015.
In children aged
Pri otrocih,
The European Commission granted a marketing authorisation valid throughout the European Union for CellCept on 14 February 1996.
Evropska komisija je dovoljenje za promet z zdravilom CellCept, veljavno po vsej Evropski uniji, izdala 14. februarja 1996.
What measures are being taken to ensure the safe and effective use of CellCept?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila CellCept?
This makes them less effective at recognising and attacking the transplanted organ, lowering the risk of the organ being rejected.
Posledično ti niso tako učinkoviti pri prepoznavanju in napadanju presajenih organov, s čimer se zmanjša tveganje zavrnitve organa.
The full EPAR for CellCept can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo CellCept je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
This is a summary of the European public assessment report (EPAR) for CellCept.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo CellCept.
The most serious risk associated with CellCept is the possible development of cancer, particularly lymphoma and skin cancer.
Najbolj resno tveganje, povezano z zdravilom CellCept, je možnost pojava raka, še zlasti limfoma in kožnega raka.
There will also be very close monitoring of the outcomes of any accidentally exposed pregnancies.
Poleg tega bo podrobno spremljala izide morebitnih nenamernih nosečnosti.
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom between two and 18 years, the dose of CellCept is calculated depending on height and weight and should be given by mouth.
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom starih od dveh do 18 let, se odmerek zdravila CellCept izračuna glede na višino in maso bolnika, zdravilo pa se jemlje peroralno.
CellCept capsules and tablets have been studied in three studies involving a total of 1,493 adults following kidney transplant, in one study involving 650 adults following heart transplant and in one study involving 565 adults following liver transplant.
Kapsule in tablete zdravila CellCept so raziskali v treh študijah, ki so vključevale skupno 1 493 odraslih po presaditvi ledvic, v eni študiji, ki je vključevala 650 odraslih po presaditvi srca, in eni študiji, ki je vključevala 565 odraslih po presaditvi jeter.
This enzyme is important for the formation of DNA in cells, particularly in the lymphocytes (a type of white blood cell which is involved in the rejection of organ transplants).
Ta encim je pomemben za tvorjenje DNK v celicah, še zlasti v limfocitih (vrsti belih krvničk, ki sodelujejo pri zavračanju presajenih organov).
In all of the studies, all of the patients also received ciclosporin and corticosteroids, and the main measure of effectiveness was the proportion of patients whose new organ had been rejected after six months.
V vseh študijah so vsi bolniki prejemali tudi ciklosporin in kortikosteroide, glavno merilo učinkovitosti pa je bil delež bolnikov, pri katerih je po šestih mesecih telo zavrnilo novi organ.
The most common side effects with CellCept used in combination with ciclosporin and corticosteroids (seen in more than 1 patient in 10) are sepsis (blood infection), gastrointestinal candidiasis (a fungal infection of the stomach or gut), urinary tract infection (infection of the structures that carry urine), herpes simplex (a viral infection that causes cold sores), herpes zoster (a viral infection that causes chickenpox and shingles), leucopenia (low white blood cell counts), thrombocytopenia (low blood platelet counts), anaemia (low red blood cell counts), vomiting, abdominal (tummy) pain, diarrhoea and nausea (feeling sick).
Najpogostejši neželeni učinki, ki so bili opaženi pri uporabi zdravila CellCept v kombinaciji s ciklosporinom in kortikosteroidi (opaženi pri več kot 1 bolniku od 10), so sepsa (okužba krvi), gastrointestinalna kandidoza (glivična okužba želodca ali črevesja), okužba urinarnega trakta (okužba struktur za odvajanje urina), herpes simpleks (virusna okužba, ki povzroča značilne kožne mehurčke), herpes zoster (virusna okužba, ki povzroča norice in pasasti izpuščaj), levkopenija (nizko število belih krvničk), trombocitopenija (nizko število trombocitov), anemija (nizko število rdečih krvničk), bruhanje, trebušne bolečine, driska in navzeja (slabost).
CellCept treatment should be initiated and maintained by a qualified transplant specialist.
Zdravljenje z zdravilom CellCept mora začeti in voditi specialist za presaditve.
The CHMP decided that CellCept's benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila CellCept večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The dose may need to be adjusted in patients with liver or kidney disease.
Odmerek bo morda treba prilagoditi pri bolnikih z okvarami ledvic ali jeter.
Other information about CellCept
Druge informacije o zdravilu CellCept
Therefore, CellCept must not be used during pregnancy unless there is no suitable alternative to prevent rejection of the transplant.
Zato se zdravilo ne sme jemati med nosečnostjo, razen če ni na voljo nobenega drugega nadomestnega zdravljenja za preprečevanje zavrnitve presadka.
The way that CellCept should be given and the dose depend on the type of organ transplant and the patient's age and size.
Način jemanja zdravila CellCept in odmerek sta odvisna od vrste presajenega organa ter starosti in velikosti bolnika.
It can also be given as an infusion lasting two hours starting within 24 hours after the transplant, for up to 14 days.
Zdravilo se lahko daje tudi kot infuzija, ki traja dve uri in se začne dajati v 24 urah po presaditvi ter se daje največ 14 dni.
It is used with ciclosporin and corticosteroids (other medicines used to prevent organ rejection).
Uporablja se skupaj s ciklosporinom in kortikosteroidi (drugimi zdravili za preprečevanje zavrnitve presajenih organov).
Women must not breastfeed while using CellCept and patients should not donate blood or sperm during treatment or for a period afterwards.
Med jemanjem zdravila CellCept ženske ne smejo dojiti, bolniki pa med zdravljenjem in še nekaj časa po njegovem zaključku ne smejo darovati krvi ali sperme.
The company that markets CellCept will provide educational materials for patients and healthcare professionals explaining the risk of harm to a developing baby and the precautions and measures to be taken to avoid pregnancy during treatment.
Družba, ki trži zdravilo CellCept, bo pripravila izobraževalno gradivo za bolnike in zdravstvene delavce, v katerem bodo pojasnjeni tveganja za poškodbe še nerojenega otroka in preventivni ukrepi za preprečitev nosečnosti med zdravljenjem.
It is available as capsules (250 mg), tablets (500 mg), a powder to be made up into an oral suspension (1 g/5 ml) and a powder to be made up into a solution for infusion (drip) into a vein (500 mg).
Zdravilo je na voljo v obliki kapsul (250 mg), tablet (500 mg), praška za pripravo peroralne suspenzije (1 g/5 ml) in praška za pripravo raztopine za infundiranje (kapalne infuzije v veno; 500 mg).
What benefit has CellCept shown during the studies?
Kakšne koristi je zdravilo CellCept izkazalo med študijami?
For more information about treatment with CellCept, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom CellCept preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
CellCept is used to prevent the body from rejecting a transplanted kidney, heart or liver.
Zdravilo CellCept se uporablja, da bi telesu preprečili zavrnitev presajenih organov, in sicer ledvic, srca ali jeter.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for CellCept.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Safety information has also been included in the summary of product characteristics and the package leaflet for CellCept, including the appropriate precautions to be followed by healthcare professionals and patients.
V povzetek glavnih značilnosti zdravila in navodilo za uporabo za zdravilo CellCept so bile vključene tudi informacije o varnosti, vključno z ustreznimi previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
Both men and women must use highly effective contraception before, during and for a suitable period after CellCept treatment.
Moški in ženske morajo pred začetkom zdravljenja z zdravilom CellCept, ves čas med njim in dovolj časa po koncu prejemanja zdravila uporabljati učinkovito kontracepcijsko zaščito.
CellCept was compared with azathioprine (another anti-rejection medicine) in all studies except for one of the kidney transplant studies, in which it was compared with placebo (a dummy treatment).
Zdravilo CellCept so v vseh študijah primerjali z azatioprinom (drugo vrsto zdravil proti zavračanju presadkov), razen v eni študiji pri presaditvah ledvic, v kateri so ga primerjali s placebom (zdravilom brez zdravilne učinkovine).